Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...

The funding will accelerate the development of Fuse's technology platform and pipeline of novel gene therapies. With its ...

Looking forward, greater use of column chromatography technologies in vector manufacturing could facilitate the adoption of ...

OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global ...

A study led by UMass Chan researchers demonstrated that a gene therapy to correct a mutation that causes maple syrup urine ...

New gene therapy for maple syrup urine disease shows promise in preventing deadly symptoms in cows and offers hope for patients.

Researchers from the NIHR Moorfields Biomedical Research Centre and University College London have found that gene therapy improved visual acuity and preserved retinal structure in young children with ...

Solid Biosciences reported recent positive data in developing their gene therapy candidate SGT-003. The phase 1/2 INSPIRE ...

Luxturna and other Spark pipeline candidates use an adeno-associated virus vector (AVV) platform to deliver its gene therapy, a distinct technology which Novartis hasn’t built up expertise in.

A study led by UMass Chan researchers demonstrated that a gene therapy to correct a mutation that causes maple syrup urine disease (MSUD) prevented newborn death, normalized growth, restored ...